

Comparison of Endoscopic Discectomy Versus Non-Endoscopic Discectomy for Symptomatic Lumbar Disc Herniation: A Systematic Review and Meta-Analysis

Global Spine Journal 2022, Vol. 12(5) 1012–1026 © The Author(s) 2021 Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/21925682211020696 journals.sagepub.com/home/gsj



Wei-Shang Li, MD¹, Qi Yan, MD², and Lin Cong, PhD¹

Abstract

Study Design: Systematic review.

Objective: The authors aimed to systematically compare the effectiveness and safety of endoscopic discectomy (ED) with nonendoscopic discectomy (NED) for treatment of symptomatic lumbar disc herniation (LDH).

Methods: A systematic search was performed on PubMed, EMBASE, the Cochrane Library and China National Knowledge Infrastructure for randomized controlled trial from inception until August 13, 2020. Trials which investigated multiple operative approaches on lumbar disc herniation were identified without language restrictions.

Results: In total, 25 trials involving 2258 patients with symptomatic LDH were included. Twenty trials performed the comparison between ED and NED. Five trials performed the comparison between percutaneous endoscopic transforaminal discectomy (PETD) and percutaneous endoscopic interlaminar discectomy (PEID). The operative time of micro-endoscopic discectomy (MED) was longer than open discectomy (OD). The length of hospital stay of percutaneous endoscopic lumbar discectomy (PELD) was shorter than fenestration discectomy (FD). Significant differences in intraoperative blood loss volumes were found between PELD with FD and MED with OD. The complication rate of PELD was lower than FD (PELD: 4.3%; FD: 14.6%) and the complication rate of full-endoscopic discectomy (MD) (FE: 13.4%; MD: 32.1%).

Conclusions: PELD and FE have the advantage of limiting intraoperative damages. ED and NED can be both considered sufficient to achieve good clinical outcomes. PETD and PEID are able to achieve similar results but the learning curve of PETD was steeper. More independent high-quality RCTs with sufficiently large sample sizes performing cost-effectiveness analyzes are needed.

Keywords

symptomatic lumbar disc herniation, endoscopic discectomy, non-endoscopic discectomy, meta-analysis, systematic review

Abbreviations

1. ED, endoscopic discectomy; 2. NED, non-endoscopic discectomy; 3. PELD, percutaneous endoscopic lumbar discectomy; 4. PETD, percutaneous endoscopic transforaminal discectomy; 5. PEID, percutaneous endoscopic interlaminar discectomy; 6. MED, micro-endoscopic discectomy; 7. OD, open discectomy; 8. MD, microscopic discectomy; 9. FD, fenestration discectomy; 10. FE, full-endoscopic discectomy; 11. LDH, lumbar disc herniation; 12. ODI, Oswestry disability index; 13. JOA, Japanese Orthopedic Association back pain evaluation questionnaire; 14. VAS, visual analog scale; 15. MD, mean difference; 16. OR, odds ratios; 17. 95% CI, 95% confidence interval; 18. SMD, standardized mean difference; 19. RCT, randomized controlled trials; 20. Exp, experimental group; 21. Clt, control group; 22. NA, not available

¹ Department of Orthopedic Surgery, The First Hospital of China Medical University, Shenyang, People's Republic of China

² Departments of Surgery, University of Texas Health San Antonio, San Antonio, TX, USA

Corresponding Author:

Lin Cong, Department of Orthopedic Surgery, The First Hospital of China Medical University, No.155 Nanjing Bei Street, Heping District, Shenyang City, Liaoning Province 110001, People's Republic of China. Email: chinaconglin@outlook.com



Creative Commons Non Commercial No Derivs CC BY-NC-ND: This article is distributed under the terms of the Creative Commons Attribution-Non Commercial-NoDerivs 4.0 License (https://creativecommons.org/licenses/by-nc-nd/4.0/) which permits non-commercial use, reproduction and distribution of the work as published without adaptation or alteration, without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

Introduction

Globally, 20 percent of low back and leg pain are caused by lumbar disc herniation (LDH)¹ and LDH is also the most common cause of adults' sciatica.² Though the low back pain of LDH can be self-limiting, it still can incur significant financial costs and physical disabilities.³ The majority of patients can recover by conservative treatment without the necessity of surgery. But after the conservative treatment has failed, surgery is indicated for symptomatic LDH. The first surgical treatment of symptomatic LDH was described by Mixter and Barr in 1934.⁴ A minimally invasive surgery for treating symptomatic LDH was reported by Caspar and Yasargil with the introduction of the microscope in 1977.^{5,6} Micro-endoscopic discectomy (MED) was described by Foley and Smith as a minimally invasive trans-muscular approach using advanced optics. Uni-portal arthroscopic microdiscectomy was reported by Kambin and bi-portal lumbar nucleotomy was reported by Schreiber and Leu in 1991.^{8,9} Percutaneous endoscopic lumbar discectomy (PELD) was introduced by Mayer in 1992.¹⁰ Thomas Hoogland Endoscopic Spine System (TESSYS) was developed by Hoogland in 1994¹¹ and the Yeung Endoscopic Spine System (YESS) was developed by Yeung in 1997.¹² PELD can be classified to percutaneous endoscopic transforaminal discectomy (PETD) or percutaneous endoscopic interlaminar discectomy (PEID) according to the surgical approach. More recently, full-endoscopic discectomy (FE) was introduced by Ruetten as a minimally invasive access to the spinal canal under continuous visualization, either via a transforaminal or interlaminar corridor.¹³

The first meta-analysis comparing the effectiveness and safety of endoscopic discectomy with open discectomy (OD) for symptomatic LDH was performed by us in 2015.¹⁴ Due to the lack of data at that time, we put these kinds of discectomy (MED, PELD and FE) together into 1 group named as endoscopic discectomy and compared them with open discectomy in the meta-analysis of 2015, which was actually not scientific and fastidious enough. Since then, many meta-analyzes similar to our previous study have appeared performing the comparison between endoscopic discectomy (ED) and non-endoscopic discectomy (NED). However, the conclusions remain inconsistent. Now that there is enough data for us to perform a series of brand-new comparisons and subgroup analyzes based on each surgical procedures of MED, PELD and FE for conducting more scientific and comprehensive results. Considering whether any kind of ED is more effective and safer than NED is still unclear, we performed this study to systematically compare the effectiveness and safety of endoscopic discectomy with non-endoscopic discectomy for treatment of symptomatic LDH. The findings of this study could provide surgeons and patients with not only the choice of open discectomy or endoscopic discectomy, but also a more thorough and accurate selection of each surgical procedures on discectomy.

Materials and Methods

Search Methods and Selection Criteria

A systematic search was performed on PubMed, EMBASE, the Cochrane Library and China National Knowledge Infrastructure (CNKI) for randomized controlled trial from inception until August 13, 2020. Randomized controlled trials which investigated multiple operative approaches on lumbar disc herniation were identified without language restrictions. Endoscopic discectomy, percutaneous endoscopic transforaminal discectomy, micro-endoscopic discectomy and lumbar disc herniation were used as key words. The review protocols were registered on PROSPERO (International Prospective Register of Systematic Reviews number, CRD42020209478).

Trials were included according to the following criteria: (1) performed the comparison between ED (PELD or MED or FE) and NED (OD or MD or FD or MD); (2) the interventions of trials were PETD and PEID; (3) participants were adults who suffer lumbar disc herniation and failed with conservative treatment; (4) contained at least 1 outcome of interest. Trials were excluded if: Interventions were different from the previous description; Or original data was lost after confirmation with corresponding author.

Data Extraction and Statistical Analyzes

Two researchers extracted the data independently. Characteristics of trials and outcomes of interest were extracted and checked carefully. The primary outcomes were operative time, length of hospital stay, blood loss volume and complication rate between ED and NED. Secondary outcomes were clinical outcomes evaluated by the Macnab criteria, reoperation rate, recurrence rate, visual analog scale (VAS), Oswestry Disability Index (ODI), Japanese Orthopedic Association back pain evaluation questionnaire (JOA) between ED and NED and fluoroscopy times, operative time, postoperative bedrest time, clinical outcomes evaluated by the Macnab criteria, complication rate, recurrence rate, ODI and VAS between PETD and PEID. To compare the effect of multiple surgical techniques more precisely, subgroup analyzes were performed based on the interventions of trials. The continuous outcomes were analyzed using mean difference (MD) and 95% confidence interval (CI). Odds ratio (OR) and 95% CI were used for dichotomous outcomes. Standardized mean difference (SMD) was used when a continuous outcome is presented with different units. All analyzes were performed by RevMan software (version 5.3). Between study heterogeneity were evaluated using Chi-squared test and I^2 . If the P value was < .05, statistical heterogeneity exists. In this situation, a random-effects model was utilized. P < .05 was considered to be statistically significant.

Assessment of Risk of Bias

The Cochrane Collaboration's risk-of-bias criteria was used for evaluating the risk of bias in each included trial. The




Figure 1. The flow-diagram showing the selection process of RCTs for meta-analysis.

classifications of bias were based on 7 items: random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias) and other bias. Each item was rated as low risk, unclear risk, or high risk.

Results

Study Selection and Characteristics

A total of 2379 studies were identified yielding 1281 studies after removal of duplications. Title and abstract screening excluded 1225 trials. After removing duplications and fulltext screening, 31 trials were eliminated. In the end, 25 trials which met the eligibility criteria were included in this study (Figure 1).

Twenty-five trials involving 2,258 patients with symptomatic LDH were included in this study. Twenty trials performed the comparison between ED and NED.¹⁵⁻³⁴ Five trials performed the comparison between PETD and PEID.³⁵⁻³⁹ Among those trials comparing ED with NED, PELD was performed in 10 trials,^{16,20,22-26,31,33,34} FE in 4 trials^{21,28-30} and MED in 6 trials.^{15,17-19,27,32} The characteristics of the included trials were shown in Table 1 and Table 2.

ED VS NED

The operative time of MED was longer than OD (open discectomy) (MD: 18.79; 95% CI: [7.82, 29.76], P < .001, $I^2 = 88\%$). No significant differences were found in operative time

Table I. Characteristics of the Included Trials.

Trial	Interventions (Exp/ Clt)	Sample size (Exp/ Clt)	Mean age (Year, Exp/ Clt)	Female (%, Exp/ Clt)	Mean duration of symptom (months, Exp/ Clt)	Mean follow-up (months)
Garg, ¹⁵ 2011	MED/ OD	112 (55/ 57)	37.5 (37.0/38.0)	34.5/ 22.8	11.6 ± 9.5/16.7 ± 15.2	12.0
Gibson, ¹⁶ 2016	PETD/ MD	140 (70/ 70)	40.5 (42.0/39.0)	57.0/ 43.0	18.0 (4.0-120.0)/ 15.0 (3.0-120.0)	24.0
Hermantin, ¹⁷ 1999	VAMD/ OD	60 (30/ 30)	39.5 (39.0/40.0)	26.7/ 43.3	ŇA	24.0
Huang, ²⁹ 2005	MED/ OD	22 (10/ 12)	39.5 (39.2/39.8)	40.0/ 25.0	NA	18.9
Hussein, ¹⁸ 2014	MED/ OD	185 (95/ 90)	30.8 (30.2/31.5)	44.2/51.1	3.0/ 3.5	102.8
Jin, ³⁴ 2017	PETD/ FD	90 (45/ 45)	41.0 (40.1/41.9)	40.0/ 44.4	24.5 \pm 13.1/ 25.5 \pm 12.8	13.0
Lee, ²⁰ 2006	PELD/ MD	60 (30/ 30)	39.5 (39.3/39.6)	26.7/ 26.7	NA	37.5
Liu, ³³ 2014	PETD/ FD	80 (40/ 40)	41.1 (39.8/42.4)	40.0/ 47.5	25.4 \pm 12.8/ 23.7 \pm 12.5	19.0
Mayer, ²¹ 1993	PELD/ MD	40 (20/ 20)	41.3 (39.8/42.7)	40.0/ 30.0	6.9/ 7.3	24.0
Pan, ²² 2014	PELD/ OD	20 (10/ 10)	NA	NA	NA	0.1
Pan, ²³ 2016	PETD/ FD	106 (48/ 58)	41.3 (39.5/42.8)	45.8/ 46.6	15.5 (5.0-72.0)/ 22.3 (0.2-84.0)	17.0
Righesso, ²⁴ 2007	MED/ OD	40 (21/ 19)	43.9 (42.0/46.0)	52.4/31.6	2.0 (1.0-7.0)/ 2.0 (1.0-6.0)	36.1
Ruetten, ²⁵ 2008	FE/ MD	200 (100/ 100)	43.0 (NA)	NA	2.7	24.0
Ruetten, ²⁶ 2009	FE/ MD	100 (50/ 50)	39.0 (NA)	NA	2.3	24.0
Komp, ¹⁹ 2015	FE/ MD	160 (80/ 80)	62.0 (NA)	NA	17.0	24.0
Tacconi, ²⁷ 2020	FE/ MD	50 (25/ 25)	44.0 (43.0/45.0)	48.0/52.0	NA	22.0
Tang, ³² 2012	PETD/ FD	80 (40/ 40)	64.7 (NA)	NA	122.4 ± 21.6	24.0
Teli, ²⁸ 2010	MED/ OD&MD	212 (70/ 142)	39.3 (39.0/39.5)	35.7/ 33.8	2.8 \pm 1.3/ 2.9 \pm 1.4	26.0
Wang, ³¹ 2015	PETD/ FD	96 (48/ 48)	45.0 (42.8/47.2)	41.7/ 45.8	NA	12.0
Wu, ³⁰ 2016	PETD/ FD	50 (25/ 25)	45.2 (46.3/44.1)	48.0/ 40.0	NA	17.3
Chen,35 2015	PETD/PEID	76 (40/ 36)	48.7 (49.5/47.9)	50/41.7	9.0	15.6
Huang, ³⁶ 2017	PETD/PEID	82 (41/ 41)́	41.3 (41.8/40.8)	26.8/ 36.6	7.12 \pm 0.72/ 7.08 \pm 0.49	12.0
Mo, ³⁹ 2019	PETD/PEID	40 (20/ 20)	42.1 (40.9/43.3)	38.5/ 56.I	NA –	16.7
Nie, ³⁸ 2016	PETD/PEID	60 (30/ 30)́	37.4 (36.6/38.2)	40.0/ 33.3	NA	27.7
Xu, ³⁷ 2013	PETD/PEID	68 (31/ 37)	47.3 (46.6/47.9)	45.2/ 29.7	7.0	3.0

Abbreviations: PELD, percutaneous endoscopic lumbar discectomy; PETD, percutaneous endoscopic transforaminal discectomy; PEID, percutaneous endoscopic interlaminar discectomy; MED, micro-endoscopic discectomy; OD, open discectomy; MD, microscopic discectomy; FD, fenestration discectomy; FE, full-endoscopic discectomy; NA, not available; Exp, experimental group; Clt, control group.

between PELD with MD (microscopic discectomy) (MD: -10.91; 95% CI: [-24.13, 2.32], P = .11, $I^2 = 78\%$) and PELD with FD (fenestration discectomy) (MD: 5.63; 95% CI: [-11.94, 23.20], P = .53, $I^2 = 98\%$). The length of hospital stay of PELD was shorter than FD (SMD: -2.41; 95% CI: [-3.48, -1.33], P < .001, $I^2 = 96\%$). And there was no significant difference between MED with OD in the length of hospital stay (SMD: -2.55; 95% CI: [-5.67, 0.56], P = .11, $I^2 = 99\%$). Significant differences were found in intraoperative blood loss volume between PELD with FD (MD: -53.42; 95% CI: [-67.75, -39.09], P < .001, $I^2 = 98\%$) and MED with OD (MD: -151.01; 95% CI: [-288.22, -13.80], P = .03, $I^2 = 98\%$) (Figure 2).

No statistical significance was found in clinical outcomes evaluated by the Macnab criteria between MED with OD (OR: 4.44; 95% CI: [0.33, 59.38], P = .26, $I^2 = 65\%$) and PELD with FD (OR: 1.47; 95% CI: [0.58, 3.74], P = .42, $I^2 = 0\%$) and PELD with OD (OR: 1.53; 95% CI: [0.23, 10.04], P = .66, $I^2 = 0\%$). The complication rate of PELD was lower than FD (PELD: 4.3%; FD: 14.6%; OR: 0.27; 95% CI: [0.09, 0.85], P = .03, $I^2 = 0\%$) and the complication rate of FE was lower than MD (FE: 13.4%; MD: 32.1%; OR: 0.32; 95% CI: [0.20, 0.52], P < .001, $I^2 = 0\%$). The complication rate of MED was slightly higher than OD however this was not statistically significant (MED: 19.5%; OD: 16.6%; OR: 1.27; 95% CI: [0.60, 2.68],

 $P = .53, I^2 = 49\%$). There was no significant difference in the rate of reoperation between MED with OD (MED: 6.3%; OD: 6.0%; OR: 1.03; 95% CI: [0.51, 2.06], $P = .93, I^2 = 14\%$) and FE with MD (FE: 6.1%; MD: 7.0%; OR: 0.86; 95% CI: [0.42, 1.76], $P = .69, I^2 = 0\%$). And no significance in the rate of recurrence was found between MED with OD (MED: 5.0%; OD: 2.5%; OR: 1.93; 95% CI: [0.74, 5.04], $P = .18, I^2 = 0\%$) and FE with MD (FE: 6.6%; MD: 5.4%; OR: 1.24; 95% CI: [0.45, 3.42], $P = .68, I^2 = 0\%$). (Figure 3).

Significant difference was found between PETD with FD in VAS at 1 day after operation (MD: -1.27; 95% CI: [-2.47, -0.07], P = .04, $I^2 = 96\%$). And there was no significant difference between PETD with FD in VAS at 3 days (MD: -1.56; 95% CI: [-4.29, 1.18], P = .26, $I^2 = 99\%$), 3 months (MD: -0.10; 95% CI: [-0.29, 0.09], P = .31, $I^2 = 0\%$) and 1 year (MD: -0.14; 95% CI: [-0.34, 0.06], P = .17, $I^2 = 33\%$) after operation. No significant difference was found between PETD with FD in ODI at 1 month (MD: -0.74; 95% CI: [-1.59, 0.11], P = .09, $I^2 = 91\%$), 3 months (MD: 0.03; 95% CI: $[-0.22, 0.28], P = .81, I^2 = 2\%), 6 \text{ months (MD: } -1.01; 95\%$ CI: $[-2.66, 0.63], P = .23, I^2 = 97\%$ and 1 year (MD: -0.42; 95% CI: [-0.98, 0.13], P = .13, $I^2 = .87\%$) after operation. No significant difference was found between PETD with FD in JOA (MD: 0.11; 95% CI: [-0.38, 0.60], P = .65, $I^2 = 36\%$) (Table 3).

Table 2. Outcomes of	of the	Included	Trials.
----------------------	--------	----------	---------

Trial	Outcomes
Garg, ¹⁵ 2011	Operative time, length of hospital stay, blood loss volume, complication, reoperation, recurrence
Gibson, ¹⁶ 2016	Operative time, complication, reoperation
Hermantin, ¹⁷ 1999	Complication, reoperation, satisfaction
Huang, ²⁹ 2005	Operative time, length of hospital stay, blood loss volume, Macnab criteria
Hussein, ¹⁸ 2014	Operative time, length of hospital stay, blood loss volume, Macnab criteria, complication, reoperation, recurrence
Jin, ³⁴ 2017	Operative time, length of hospital stay, Macnab criteria, complication, VAS, ODI
Lee, ²⁰ 2006	Macnab criteria
Liu, ³³ 2014	Operative time, length of hospital stay, blood loss volume, Macnab criteria, VAS, ODI, JOA
Mayer, ²¹ 1993	Operative time
Pan, ²² 2014	Macnab criteria
Pan, ²³ 2016	Operative time, length of hospital stay, blood loss volume, Macnab criteria, complication, ODI, JOA
Righesso, ²⁴ 2007	Operative time, complication, reoperation, recurrence
Ruetten, ²⁵ 2008	Complication, reoperation, recurrence, satisfaction
Ruetten, ²⁶ 2009	Complication, reoperation, recurrence, satisfaction
Komp, ¹⁹ 2015	Complication, reoperation
Tacconi, ²⁷ 2020	Complication, reoperation
Tang, ³² 2012	Operative time, length of hospital stay, blood loss volume, VAS, ODI
Teli, ²⁸ 2010	Operative time, length of hospital stay, complication, reoperation, recurrence
Wang, ³¹ 2015	Operative time, length of hospital stay, blood loss volume, VAS, ODI, JOA
Wu, ³⁰ 2016	Operative time, length of hospital stay, blood loss volume, VAS, ODI, JOA
Chen, ³⁵ 2015	Operative time, Macnab criteria, VAS
Huang, ³⁶ 2017	Fluoroscopy times, recurrent disc herniation, operative time, VAS, ODI
Mo, ³⁹ 2019	Fluoroscopy times, operative time, postoperative bed time, Macnab criteria, complication, VAS, ODI
Nie, ³⁸ 2016	Fluoroscopy times, operative time, postoperative bed time, Macnab criteria, complication, recurrent disc herniation
Xu, ³⁷ 2013	Fluoroscopy times, operative time, Macnab criteria, VAS

Abbreviations: VAS, visual analog scale; ODI, Oswestry disability index; JOA, Japanese Orthopaedic Association back pain evaluation questionnaire.

PETD VS PEID

No significant difference was found between PETD with PEID in VAS-back (MD: -0.39; 95% CI: [-1.08, 0.30], P = .27, $I^2 = 88\%$), VAS-leg (MD: -0.08; 95% CI: [-0.45, 0.29], P = .68, $I^2 = 49\%$), ODI (MD: 0.05; 95% CI: [-1.86, 1.96], P = .96, $I^2 = 0\%$) and postoperative bedrest time (MD: -0.95; 95% CI: $[-2.01, 0.11], P = .08, I^2 = 88\%$). The fluoroscopy time of PETD was more than PEID (MD: 13.36; 95% CI: [6.57, 20.14], P < .001, $I^2 = 99\%$). And the operative time of PETD was longer than PEID (MD: 14.63; 95% CI: [5.80, 23.45], P =.001, $I^2 = 92\%$). No statistical significance was found between PETD with PEID in clinical outcomes evaluated by the Macnab criteria (OR: 1.02; 95% CI: [0.46, 2.24], P = .96, $I^2 = 0\%$), complication rates (PETD: 8.7%; PEID: 7.0%; OR: 1.09; 95% CI: [0.13, 9.49], P = .94, $I^2 = 56\%$) and recurrence rates (PETD: 11.6%; PEID: 14.3%; OR: 0.79; 95% CI: [0.29, 2.17], P = .65, $I^2 = 0\%$) (Figure 4).

Risk of Bias

All trials described the appropriate random sequence generation and 5 trials reported the allocation concealment.^{16,19,21,24,30} One trial was a double-blind randomized controlled trial among participants.³⁰ Trial of Teli³² et al failed to report some of the original data. We tried to contact the corresponding author but was unsuccessful. Dural leaks occurred in earlier patients in Grag et al¹⁵ and physicians were able to override decision for type of surgery in the trial of Hermantin et al,¹⁷ which are the reasons why the other bias of these trials were high risk (Figure 5).

Discussion

In this study, we included 20 RCTs that performed the comparison between ED and NED. In MED, air is the medium. A small incision is performed and a tubular retractor (16- or 18-mm in diameter) is used to approach the herniated disc posteriorly using an endoscope.²⁷ PELD is a minimally invasive discectomy with water as medium. With patients under local anesthesia in PETD or general anesthesia in PEID a needle is used to locate the herniated disc under fluoroscopic imaging. An endoscope is then introduced along the needle to perform decompression under direct visualization.^{22,25} FE evolved from PELD but access the herniated disc posterolaterally.²⁸ Significant differences were found between PELD with FD and MED with OD in intraoperative blood loss volume. Nakagawa et al concluded that MED was superior to OD in the control of intraoperative injury.⁴⁰ However, most of included studies (5/6) were non-randomized controlled trials in the study of Nakagawa et al,⁴⁰ which could lead to biases of results and weakened the reliability of that conclusion. And we believed that intraoperative injury should be a composite result of multiple factors and should be reflected not only in terms of intraoperative bleeding, but also in other aspects such as operative time and hospital stay. The results of our study




Figure 2. Pooling results of the ED group and the NED group. The results were shown as follows: Operative Time, Hospital Stay and Intraoperative Blood Loss.

suggest that MED is superior to OD in controlling the amount of intraoperative blood loss. As for PELD and FE, drainage systems were not placed intraoperatively. Water pressure can promote hemostasis, and the surgeon does not need to spend more time and energy on hemostasis during operation. For operative time, no significant differences were found between

		IED	OD/F)		Odds Ratio	Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl	
Macnab criteria PELD	VS FD							
Jin2017	42	45	40	45	38.8%	1.75 [0.39, 7.81]		
Liu2014	37	40	36	40	35.4%	1.37 [0.29, 6.56]		
Pan2016	46	48	55	58	25.8%	1.25 [0.20, 7.83]		
Subtotal (95% CI)		133			100.0%	1.47 [0.58, 3.74]		
Total events	125		131					
Heterogeneity: Tau ² = Test for overall effect:	0.00; Chi ² :		if = 2 (P =	= 0.96);	l² = 0%			
Macnab criteria PELD	VS OD							
Lee2006	29	30	28	30	58.6%	2.07 [0.18, 24.15]		
Pan2014	9	10	9	10	41.4%	1.00 [0.05, 18.57]	_	
Subtotal (95% CI)	•	40			100.0%	1.53 [0.23, 10.04]		
Total events	38		37					
Heterogeneity: Tau ² = Test for overall effect:	0.00; Chi ² :		if = 1 (P =	= 0.71);	l ² = 0%			
Macnab criteria MED V	S OD							
Huang2005	9	10	11	12	37.9%	0.82 [0.04, 15.00]		
Hussein2014	92	95	64	90	62.1%	12.46 [3.62, 42.92]		
Subtotal (95% CI)		105			100.0%	4.44 [0.33, 59.38]		_
Total events	101		75			,		
Heterogeneity: Tau ² = Test for overall effect:	2.42; Chi ² :		if = 1 (P =	= 0.09);	l² = 65%			
						⊢		
						0.01	0.1 1 10 PELD/MED OD/FD	100
			00/110					
Study or Subarour	PELD/ME Events		OD/MD/		l Mainhé	Odds Ratio	Odds Ratio	
Study or Subgroup			Events	IOTA	i weight	M-H, Random, 95% Cl		
amplication DELD VC		Total	LTOING	1010	-		M-H, Random, 95% Cl	
	FD				- 05.00/			
Jin2017	FD 1	45	3	45		0.32 [0.03, 3.18]		
Jin2017 Pan2016	FD	45 48		45 58	3 75.0%	0.32 [0.03, 3.18] 0.26 [0.07, 0.97]		
Jin2017 Pan2016 Subtotal (95% CI)	FD 1 3	45	3 12	45 58		0.32 [0.03, 3.18] 0.26 [0.07, 0.97]		
Jin2017 Pan2016 Subtotal (95% CI) Total events	FD 1 3	45 48 93	3 12 15	45 58 103	3 75.0% 3 100.0%	0.32 [0.03, 3.18] 0.26 [0.07, 0.97]		
Jin2017 Pan2016 Subtotal (95% CI)	FD 1 3 4 0.00; Chi ² =	45 48 93 : 0.03, d	3 12 15	45 58 103	3 75.0% 3 100.0%	0.32 [0.03, 3.18] 0.26 [0.07, 0.97]		
Jin2017 Pan2016 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 complication FE VS ME	FD 1 3 4 0.00; Chi ² = Z = 2.23 (P	45 48 93 : 0.03, d	3 12 15 f = 1 (P =	45 58 103	3 75.0% 3 100.0% 1 ² = 0%	0.32 [0.03, 3.18] 0.26 [0.07, 0.97] 0.27 [0.09, 0.85]		
Jin2017 Pan2016 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2	FD 1 3 4 0.00; Chi ² = Z = 2.23 (P	45 48 93 : 0.03, d	3 12 15	45 58 103	3 75.0% 3 100.0% 1 ² = 0%	0.32 [0.03, 3.18] 0.26 [0.07, 0.97] 0.27 [0.09, 0.85]		
Jin2017 Pan2016 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 complication FE VS ME	FD 1 3 4 0.00; Chi ² = Z = 2.23 (P	45 48 93 = 0.03, d = 0.03)	3 12 15 f = 1 (P =	45 58 103 0.87); I	3 75.0% 3 100.0% 1 ² = 0% 32.9%	0.32 [0.03, 3.18] 0.26 [0.07, 0.97] 0.27 [0.09, 0.85] 0.38 [0.16, 0.90]		
Jin2017 Pan2016 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 complication FE VS ME Komp2015	FD 1 3 4 0.00; Chi ² = Z = 2.23 (P 9	45 48 93 : 0.03, d = 0.03) 80 91 45	3 12 15 f = 1 (P = 20	45 58 103 0.87); 1 80 87 42	3 75.0% 3 100.0% 3 ² = 0% 32.9% 7 40.2% 2 26.9%	0.32 [0.03, 3.18] 0.26 [0.07, 0.97] 0.27 [0.09, 0.85] 0.38 [0.16, 0.90] 0.31 [0.14, 0.66] 0.28 [0.11, 0.71]		
Jin2017 Pan2016 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 complication FE VS ME Komp2015 Ruetten2008	FD 1 3 0.00; Chi ² = Z = 2.23 (P 9 11	45 48 93 : 0.03, d = 0.03) 80 91	3 12 15 f = 1 (P = 20 27	45 58 103 0.87); 1 80 87 42	3 75.0% 3 100.0% 1 ² = 0% 0 32.9% 7 40.2%	0.32 [0.03, 3.18] 0.26 [0.07, 0.97] 0.27 [0.09, 0.85] 0.38 [0.16, 0.90] 0.31 [0.14, 0.66] 0.28 [0.11, 0.71]		
Jin2017 Pan2016 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 complication FE VS ME Komp2015 Ruetten2008 Ruetten2009	FD 1 3 0.00; Chi ² = Z = 2.23 (P 9 11	45 48 93 : 0.03, d = 0.03) 80 91 45	3 12 15 f = 1 (P = 20 27	45 58 103 0.87); 1 80 87 42	3 75.0% 3 100.0% 3 ² = 0% 32.9% 7 40.2% 2 26.9%	0.32 [0.03, 3.18] 0.26 [0.07, 0.97] 0.27 [0.09, 0.85] 0.38 [0.16, 0.90] 0.31 [0.14, 0.66] 0.28 [0.11, 0.71]		
Jin2017 Pan2016 Subtotal (95% Cl) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 complication FE VS ME Komp2015 Ruetten2008 Ruetten2009 Subtotal (95% Cl)	FD 1 3 4 0.00; Chi ² = Z = 2.23 (P 9 11 9 29 0.00; Chi ² =	45 48 93 = 0.03, d = 0.03) 80 91 45 216 = 0.27, d	3 12 15 f = 1 (P = 20 27 20 67 f = 2 (P =	45 58 103 0.87); 1 80 87 42 209	3 75.0% 3 100.0% 3 ² = 0% 32.9% 7 40.2% 2 26.9% 30.0%	0.32 [0.03, 3.18] 0.26 [0.07, 0.97] 0.27 [0.09, 0.85] 0.38 [0.16, 0.90] 0.31 [0.14, 0.66] 0.28 [0.11, 0.71]		
Jin2017 Pan2016 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 complication FE VS ME Komp2015 Ruetten2008 Ruetten2008 Ruetten2009 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2	FD 1 3 4 0.00; Chi ² = Z = 2.23 (P 9 11 9 29 0.00; Chi ² = 2 2 2 2 2 2 2 2 2 2 2 2 2	45 48 93 = 0.03, d = 0.03) 80 91 45 216 = 0.27, d	3 12 15 f = 1 (P = 20 27 20 67 f = 2 (P =	45 58 103 0.87); 1 80 87 42 209	3 75.0% 3 100.0% 3 ² = 0% 32.9% 7 40.2% 2 26.9% 30.0%	0.32 [0.03, 3.18] 0.26 [0.07, 0.97] 0.27 [0.09, 0.85] 0.38 [0.16, 0.90] 0.31 [0.14, 0.66] 0.28 [0.11, 0.71]		
Jin2017 Pan2016 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 complication FE VS ME Komp2015 Ruetten2008 Ruetten2008 Ruetten2009 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 complication MED VS (FD 1 3 4 0.00; Chi ² = Z = 2.23 (P 9 11 9 29 0.00; Chi ² = Z = 4.55 (P DD	45 48 93 : 0.03, d = 0.03) 80 91 45 216 : 0.27, d < 0.000	3 12 15 f = 1 (P = 20 27 20 67 f = 2 (P = 01)	45 58 103 0.87); 1 80 87 42 209 0.88); 1	3 75.0% 3 100.0% 1 ² = 0% 3 32.9% 7 40.2% 2 26.9% 100.0% 1 ² = 0%	0.32 [0.03, 3.18] 0.26 [0.07, 0.97] 0.27 [0.09, 0.85] 0.38 [0.16, 0.90] 0.31 [0.14, 0.66] 0.28 [0.11, 0.71] 0.32 [0.20, 0.52]		
Jin2017 Pan2016 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 complication FE VS ME Komp2015 Ruetten2008 Ruetten2009 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 complication MED VS (Garg2011	FD 1 3 4 0.00; Chi ² = 2 = 2.23 (P 9 11 9 29 0.00; Chi ² = 2 2 2 4 5 (P 0 1 1 9 29 0.00; Chi ² = 1 9 1 1 9 1 1 9 1 1 9 1 1 9 1 1 9 1 1 9 1 1 9 1 1 1 1 1 1 1 1 1 1 1 1 1	45 48 93 : 0.03, d = 0.03) 80 91 45 216 : 0.27, d < 0.000	3 12 15 f = 1 (P = 20 27 20 f = 2 (P = 01) 12	45 58 103 0.87); 1 80 87 42 209 0.88); 1 0.88); 1	 3 75.0% 3 100.0% 1² = 0% 32.9% 40.2% 2 26.9% 100.0% 1² = 0% 1² = 0% 7 26.7% 	0.32 [0.03, 3.18] 0.26 [0.07, 0.97] 0.27 [0.09, 0.85] 0.38 [0.16, 0.90] 0.31 [0.14, 0.66] 0.28 [0.11, 0.71] 0.32 [0.20, 0.52] 0.83 [0.33, 2.12]		
Jin2017 Pan2016 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 complication FE VS ME Komp2015 Ruetten2008 Ruetten2009 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 complication MED VS (Garg2011 Hermantin1999	FD 1 3 4 $2.00; Chi^2 = 2.23 (P)$ 2 2 2 2 2 2 2 2	45 48 93 = 0.03, d = 0.03) 80 91 45 216 = 0.27, d < 0.000	$\begin{array}{c} 3 \\ 12 \\ f = 1 \\ (P = 20) \\ 27 \\ 20 \\ 67 \\ f = 2 \\ (P = 20) \\ 12 \\ 2 \\ 2 \end{array}$	45 58 103 0.87); 1 80 87 42 209 0.88); 1 57 30	 3 75.0% 3 100.0% 1² = 0% 32.9% 40.2% 2 26.9% 100.0% 1² = 0% 7 26.7% 5.2% 	0.32 [0.03, 3.18] 0.26 [0.07, 0.97] 0.27 [0.09, 0.85] 0.38 [0.16, 0.90] 0.31 [0.14, 0.66] 0.28 [0.11, 0.71] 0.32 [0.20, 0.52] 0.83 [0.33, 2.12] 0.19 [0.01, 4.06] ←		
Jin2017 Pan2016 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 complication FE VS ME Komp2015 Ruetten2008 Ruetten2009 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 complication MED VS (Garg2011 Hermantin1999 Hussein2014	FD 1 3 4 $2.00; Chi^2 =$ 2 = 2.23 (P) 9 11 9 29 0.00; Chi^2 = 29 0.00; Chi^2 = 29 0.00; Chi^2 = 10 0 0 20 0 0 0 0 20 0 0 0 0 0 0 0 0 0 0 0 0 0	45 48 93 = 0.03, d = 0.03) 80 91 45 216 = 0.27, d < 0.000 55 30 90	3 12 15 f = 1 (P = 20 27 20 f = 2 (P = 01) 12 23	45 58 103 0.87); 1 80 87 42 209 0.88); 1 57 30 95	 3 75.0% 3 100.0% 12 = 0% 3 32.9% 7 40.2% 2 26.9% 3 100.0% 12 = 0% 7 26.7% 5 5.2% 5 33.2% 	0.32 [0.03, 3.18] 0.26 [0.07, 0.97] 0.27 [0.09, 0.85] 0.38 [0.16, 0.90] 0.31 [0.14, 0.66] 0.28 [0.11, 0.71] 0.32 [0.20, 0.52] 0.83 [0.33, 2.12] 0.19 [0.01, 4.06] 0.89 [0.45, 1.77]		
Jin2017 Pan2016 Subtotal (95% Cl) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 complication FE VS ME Komp2015 Ruetten2008 Ruetten2009 Subtotal (95% Cl) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 complication MED VS Cl Garg2011 Hermantn1999 Hussein2014 Righesso2007	FD 1 3 4 0.00; Chi ² = Z = 2.23 (P 9 11 9 29 0.00; Chi ² = Z = 4.55 (P 0 0 10 0 20 3	45 48 93 : 0.03, di = 0.03) 80 91 45 216 : 0.27, di < 0.000 55 30 90 21	$\begin{array}{c} 3 \\ 12 \\ 15 \\ f = 1 \ (P = 20) \\ 27 \\ 20 \\ 67 \\ 67 \\ 20 \\ 67 \\ 20 \\ 12 \\ 23 \\ 1 \end{array}$	45 58 103 0.87); 1 80 87 42 209 0.88); 1 57 30 95 15	 3 75.0% 3 100.0% 12 = 0% 3 32.9% 7 40.2% 2 26.9% 3 100.0% 12 = 0% 7 26.7% 5 5.2% 5 33.2% 8 .3% 	0.32 [0.03, 3.18] 0.26 [0.07, 0.97] 0.27 [0.09, 0.85] 0.38 [0.16, 0.90] 0.31 [0.14, 0.66] 0.28 [0.11, 0.71] 0.32 [0.20, 0.52] 0.83 [0.33, 2.12] 0.19 [0.01, 4.06] 0.89 [0.45, 1.77] 3.00 [0.28, 31.63]		
Jin2017 Pan2016 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 complication FE VS ME Komp2015 Ruetten2008 Ruetten2008 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 complication MED VS (Garg2011 Hermantin1999 Hussein2014 Righesso2007 Teli2010	FD 1 3 4 $2.00; Chi^2 =$ 2 = 2.23 (P) 9 11 9 29 0.00; Chi^2 = 29 0.00; Chi^2 = 29 0.00; Chi^2 = 10 0 0 20 0 0 0 0 20 0 0 0 0 0 0 0 0 0 0 0 0 0	45 48 93 = 0.03) = 0.03) 80 91 45 216 = 0.27, d < 0.000 55 30 90 90 21 70	3 12 15 f = 1 (P = 20 27 20 f = 2 (P = 01) 12 23	45 58 103 0.87); 1 80 87 42 209 0.88); 1 57 30 95 19 70	 3 75.0% 3 100.0% 1² = 0% 1 40.2% 2 26.9% 1 100.0% 1² = 0% 1 26.7% 5 33.2% 3 3.2% 3 8.3% 2 26.6% 	0.32 [0.03, 3.18] 0.26 [0.07, 0.97] 0.27 [0.09, 0.85] 0.38 [0.16, 0.90] 0.31 [0.14, 0.66] 0.28 [0.11, 0.71] 0.32 [0.20, 0.52] 0.19 [0.01, 4.06] 0.89 [0.45, 1.77] 3.00 [0.28, 31.63] 3.35 [1.31, 8.60]		
Jin2017 Pan2016 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 complication FE VS ME Komp2015 Ruetten2008 Ruetten2008 Ruetten2009 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 complication MED VS (Garg2011 Hermantin1999 Hussein2014 Righesso2007 Teli2010 Subtotal (95% CI)	FD 1 3 4 0.00; Chi ² = Z = 2.23 (P 9 11 9 29 0.00; Chi ² = 2 2 2 4.55 (P 0 0 0 20 3 19	45 48 93 : 0.03, di = 0.03) 80 91 45 216 : 0.27, di < 0.000 55 30 90 21	$\begin{array}{c} 3 \\ 12 \\ 15 \\ f = 1 \ (P = 20) \\ 27 \\ 20 \\ 27 \\ 20 \\ 67 \\ f = 2 \ (P = 01) \\ 12 \\ 23 \\ 1 \\ 7 \end{array}$	45 58 103 0.87); 1 80 87 42 209 0.88); 1 57 30 95 19 70	 3 75.0% 3 100.0% 12 = 0% 3 32.9% 7 40.2% 2 26.9% 3 100.0% 12 = 0% 7 26.7% 5 5.2% 5 33.2% 8 .3% 	0.32 [0.03, 3.18] 0.26 [0.07, 0.97] 0.27 [0.09, 0.85] 0.38 [0.16, 0.90] 0.31 [0.14, 0.66] 0.28 [0.11, 0.71] 0.32 [0.20, 0.52] 0.19 [0.01, 4.06] 0.89 [0.45, 1.77] 3.00 [0.28, 31.63] 3.35 [1.31, 8.60]		
Jin2017 Pan2016 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 Complication FE VS ME Komp2015 Ruetten2008 Ruetten2009 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 Complication MED VS (Garg2011 Hermantin1999 Hussein2014 Righesso2007 Teli2010 Subtotal (95% CI) Total events	FD 1 3 4 $2.00; Chi^2 =$ 2 = 2.23 (P) 0 9 11 9 29 0.00; Chi^2 = 2 = 4.55 (P) 0 10 0 20 3 19 52	45 48 93 = 0.03, d = 0.03) 80 91 45 216 = 0.27, d < 0.000 = 55 30 90 21 70 266	$\begin{array}{c} 3 \\ 12 \\ 15 \\ f = 1 \ (P = 20) \\ 27 \\ 20 \\ 67 \\ f = 2 \ (P = 20) \\ 12 \\ 23 \\ 1 \\ 7 \\ 45 \end{array}$	45 58 103 0.87); 1 80 87 42 209 0.88); 1 57 30 95 19 70 271	3 75.0% 3 100.0% 3 100.0% 3 100.0% 3 2.9% 40.2% 26.9% 40.2% 26.9% 100.0% 100.0% 7 26.7% 5 3.2.9% 9 8.3% 0 26.6% 100.0%	0.32 [0.03, 3.18] 0.26 [0.07, 0.97] 0.27 [0.09, 0.85] 0.38 [0.16, 0.90] 0.31 [0.14, 0.66] 0.28 [0.11, 0.71] 0.32 [0.20, 0.52] 0.19 [0.01, 4.06] 0.89 [0.45, 1.77] 3.00 [0.28, 31.63] 3.35 [1.31, 8.60]		
Jin2017 Pan2016 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 complication FE VS ME Komp2015 Ruetten2008 Ruetten2009 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Complication MED VS (Garg2011 Hermantin1999 Hussein2014 Righesso2007 Teli2010 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (FD 1 3 4 $2,00; Chi^2 = 2,23 (P)$ 2 2 2 2 2 2 2 2	45 48 93 : 0.03, d = 0.03) 80 91 45 216 : 0.27, d < 0.000 55 30 90 21 700 266 : 7.84, d	$\begin{array}{c} 3 \\ 12 \\ 15 \\ f = 1 \ (P = 20) \\ 27 \\ 20 \\ 67 \\ f = 2 \ (P = 20) \\ 12 \\ 23 \\ 1 \\ 7 \\ 45 \end{array}$	45 58 103 0.87); 1 80 87 42 209 0.88); 1 57 30 95 19 70 271	3 75.0% 3 100.0% 3 100.0% 3 100.0% 3 2.9% 40.2% 26.9% 40.2% 26.9% 100.0% 100.0% 7 26.7% 5 3.2.9% 9 8.3% 0 26.6% 100.0%	0.32 [0.03, 3.18] 0.26 [0.07, 0.97] 0.27 [0.09, 0.85] 0.38 [0.16, 0.90] 0.31 [0.14, 0.66] 0.28 [0.11, 0.71] 0.32 [0.20, 0.52] 0.19 [0.01, 4.06] 0.89 [0.45, 1.77] 3.00 [0.28, 31.63] 3.35 [1.31, 8.60]		
Pan2016 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 complication FE VS ME Komp2015 Ruetten2008 Ruetten2009 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Complication MED VS O Garg2011 Hermantin1999 Hussein2014 Righesso2007 Teli2010 Subtotal (95% CI) Total events	FD 1 3 4 $2,00; Chi^2 = 2,23 (P)$ 2 2 2 2 2 2 2 2	45 48 93 : 0.03, d = 0.03) 80 91 45 216 : 0.27, d < 0.000 55 30 90 21 700 266 : 7.84, d	$\begin{array}{c} 3 \\ 12 \\ 15 \\ f = 1 \ (P = 20) \\ 27 \\ 20 \\ 67 \\ f = 2 \ (P = 20) \\ 12 \\ 23 \\ 1 \\ 7 \\ 45 \end{array}$	45 58 103 0.87); 1 80 87 42 209 0.88); 1 57 30 95 19 70 271	3 75.0% 3 100.0% 3 100.0% 3 100.0% 3 2.9% 40.2% 26.9% 40.2% 26.9% 100.0% 100.0% 7 26.7% 5 3.2.9% 9 8.3% 0 26.6% 100.0%	0.32 [0.03, 3.18] 0.26 [0.07, 0.97] 0.27 [0.09, 0.85] 0.38 [0.16, 0.90] 0.31 [0.14, 0.66] 0.28 [0.11, 0.71] 0.32 [0.20, 0.52] 0.19 [0.01, 4.06] 0.89 [0.45, 1.77] 3.00 [0.28, 31.63] 3.35 [1.31, 8.60]		
Jin2017 Pan2016 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 Complication FE VS ME Komp2015 Ruetten2008 Ruetten2008 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Complication MED VS (Garg2011 Hermantin1999 Hussein2014 Righesso2007 Teli2010 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (FD 1 3 4 $2,00; Chi^2 = 2,23 (P)$ 2 2 2 2 2 2 2 2	45 48 93 : 0.03, d = 0.03) 80 91 45 216 : 0.27, d < 0.000 55 30 90 21 700 266 : 7.84, d	$\begin{array}{c} 3 \\ 12 \\ 15 \\ f = 1 \ (P = 20) \\ 27 \\ 20 \\ 67 \\ f = 2 \ (P = 20) \\ 12 \\ 23 \\ 1 \\ 7 \\ 45 \end{array}$	45 58 103 0.87); 1 80 87 42 209 0.88); 1 57 30 95 19 70 271	3 75.0% 3 100.0% 3 100.0% 3 100.0% 3 2.9% 40.2% 26.9% 40.2% 26.9% 100.0% 100.0% 7 26.7% 5 3.2.9% 9 8.3% 0 26.6% 100.0%	0.32 [0.03, 3.18] 0.26 [0.07, 0.97] 0.27 [0.09, 0.85] 0.38 [0.16, 0.90] 0.31 [0.14, 0.66] 0.28 [0.11, 0.71] 0.32 [0.20, 0.52] 0.19 [0.01, 4.06] 0.89 [0.45, 1.77] 3.00 [0.28, 31.63] 3.35 [1.31, 8.60] 1.27 [0.60, 2.68]		
Jin2017 Pan2016 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 Complication FE VS ME Komp2015 Ruetten2008 Ruetten2008 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (Complication MED VS (Garg2011 Hermantin1999 Hussein2014 Righesso2007 Teli2010 Subtotal (95% CI) Total events Heterogeneity: Tau ² = (FD 1 3 4 $2,00; Chi^2 = 2,23 (P)$ 2 2 2 2 2 2 2 2	45 48 93 : 0.03, d = 0.03) 80 91 45 216 : 0.27, d < 0.000 55 30 90 21 700 266 : 7.84, d	$\begin{array}{c} 3 \\ 12 \\ 15 \\ f = 1 \ (P = 20) \\ 27 \\ 20 \\ 67 \\ f = 2 \ (P = 20) \\ 12 \\ 23 \\ 1 \\ 7 \\ 45 \end{array}$	45 58 103 0.87); 1 80 87 42 209 0.88); 1 57 30 95 19 70 271	3 75.0% 3 100.0% 3 100.0% 3 100.0% 3 2.9% 40.2% 26.9% 40.2% 26.9% 100.0% 100.0% 7 26.7% 5 3.2.9% 9 8.3% 0 26.6% 100.0%	0.32 [0.03, 3.18] 0.26 [0.07, 0.97] 0.27 [0.09, 0.85] 0.38 [0.16, 0.90] 0.31 [0.14, 0.66] 0.28 [0.11, 0.71] 0.32 [0.20, 0.52] 0.19 [0.01, 4.06] 0.89 [0.45, 1.77] 3.00 [0.28, 31.63] 3.35 [1.31, 8.60]		100

Figure 3. Pooling results of the ED group and the NED group. The results were shown as follows: Clinical Outcomes Evaluated by the Macnab Criteria, Complication Rate, Reoperation Rate and Recurrence Rate.

PELD with MD and PELD with FD. And the operative time of MED was longer than OD. The operation time is related to the age and physical condition of the patient, the surgeon's proficiency with the procedure and the cooperation of the surgical

team, so it is difficult to compare the operative time as a separate variable. Ruan et al suggested that the operative time of PELD was shorter than that of OD.⁴¹ In their study, 5 of the 6 trials included in the comparison of operative time were non-

	MED/I		OD/N			Odds Ratio		Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C		M-H, Fixed, 95% Cl	
eoperation FE VS MD									
Komp2015	2	80	2	80	12.0%	1.00 [0.14, 7.28]			
Ruetten2008	7	92	10	92	56.9%	0.68 [0.25, 1.86]			
Ruetten2009	5	47	5	45	28.1%	0.95 [0.26, 3.54]			
Tacconi2020	1	25	0	25	2.9%	3.12 [0.12, 80.39]			
Subtotal (95% CI)		244		242	100.0%	0.86 [0.42, 1.76]		-	
Total events Heterogeneity: Chi ² = 0 Test for overall effect: 2		•		0%					
eoperation MED VS OI)								
Garg2011	1	55	0	57	3.0%	3.17 [0.13, 79.37]			
Hermantin1999	1	30	1	30	6.2%	1.00 [0.06, 16.76]			
Hussein2014	6	95	11	90	67.5%	0.48 [0.17, 1.37]			
Righesso2007	1	21	1	19	6.4%	0.90 [0.05, 15.47]			
Teli2010	8	70	3	70	16.9%	2.88 [0.73, 11.35]			
Subtotal (95% CI)	5	271	5	266	100.0%	1.03 [0.51, 2.06]			
Total events	17		16					T	
Heterogeneity: Chi ² = 4		4 (P = (14%					
Test for overall effect: Z	: = 0.08 (I	P = 0.9	3)						
							0.01	0.1 1 10	100
							0.01	MED/FE OD/MI	100
	MED/I		OD/M			Odds Ratio		Odds Ratio	
Study or Subgroup ecurrences FE VS MD	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I	M-H, Fixed, 95% Cl	
Ruetten2008	6	91	5	87	71.2%	1.16 [0.34, 3.94]			
D	3	45	2	42	28.8%	1.43 [0.23, 9.00]			
Ruetten2009	3	40							
Subtotal (95% CI)	3	136	2		100.0%	1.24 [0.45, 3.42]			
	3 9		7					-	
Subtotal (95% CI)	9 .03, df =	136 1 (P = (7 0.85); l² =	129					
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0	9 .03, df = 1 2 = 0.41 (f	136 1 (P = (7 0.85); l² =	129					
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: 2 ecurrences MED VS O	9 .03, df = 1 2 = 0.41 (f	136 1 (P = (7 0.85); l² =	129		1.24 [0.45, 3.42]			
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: 2	9 .03, df = - 2 = 0.41 (f	136 1 (P = (P = 0.6	7 0.85); I² = 8)	129 0%	100.0% 7.6%	1.24 (0.45, 3.42) 3.17 (0.13, 79.37)			
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: 2 ecurrences MED VS Of Garg2011 Hussein2014	9 .03, df = 1 2 = 0.41 (f D 1	136 1 (P = (P = 0.6 55	7 0.85); I² = 8) 0	129 0% 57	100.0%	1.24 (0.45, 3.42) 3.17 (0.13, 79.37) 0.62 (0.10, 3.82)			
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: 2 ecurrences MED VS Of Garg2011 Hussein2014 Righesso2007	9 .03, df = 1 2 = 0.41 (f D 1 2	136 1 (P = 0 P = 0.6 55 95	7 0.85); I ² = 8) 0 3	129 0% 57 90	100.0% 7.6% 48.1% 16.0%	1.24 (0.45, 3.42) 3.17 (0.13, 79.37) 0.62 (0.10, 3.82) 0.90 (0.05, 15.47)			
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: 2 ecurrences MED VS Of Garg2011 Hussein2014	9 .03, df = - 2 = 0.41 (f D 1 2 1	136 1 (P = (P = 0.6 55 95 21	7 0.85); l ² = 8) 0 3 1	129 0% 57 90 19	100.0% 7.6% 48.1%	1.24 (0.45, 3.42) 3.17 (0.13, 79.37) 0.62 (0.10, 3.82)			
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: Z ecurrences MED VS OF Garg2011 Hussein2014 Righesso2007 Teli2010 Subtotal (95% CI)	9 .03, df = - 2 = 0.41 (f D 1 2 1 8	136 1 (P = 0 P = 0.6 55 95 21 70	7 0.85); l ² = 8) 0 3 1	129 0% 57 90 19 70	7.6% 48.1% 16.0% 28.3%	1.24 (0.45, 3.42) 3.17 (0.13, 79.37) 0.62 (0.10, 3.82) 0.90 (0.05, 15.47) 4.39 (0.90, 21.45)			
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: Z ecurrences MED VS OI Garg2011 Hussein2014 Righesso2007 Teli2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 2	9 .03, df = : 2 = 0.41 (f D 1 2 1 8 8 .89, df = :	136 1 (P = (P = 0.6 55 95 21 70 241 3 (P = (7 ().85); ² = 8) 0 3 1 2 6 ().41); ² =	129 0% 57 90 19 70 236	7.6% 48.1% 16.0% 28.3%	1.24 (0.45, 3.42) 3.17 (0.13, 79.37) 0.62 (0.10, 3.82) 0.90 (0.05, 15.47) 4.39 (0.90, 21.45)			
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: Z ecurrences MED VS OF Garg2011 Hussein2014 Righesso2007 Teli2010 Subtotal (95% CI) Total events	9 .03, df = : 2 = 0.41 (f D 1 2 1 8 8 .89, df = :	136 1 (P = (P = 0.6 55 95 21 70 241 3 (P = (7 ().85); ² = 8) 0 3 1 2 6 ().41); ² =	129 0% 57 90 19 70 236	7.6% 48.1% 16.0% 28.3%	1.24 (0.45, 3.42) 3.17 (0.13, 79.37) 0.62 (0.10, 3.82) 0.90 (0.05, 15.47) 4.39 (0.90, 21.45)			
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: Z ecurrences MED VS OI Garg2011 Hussein2014 Righesso2007 Teli2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 2	9 .03, df = : 2 = 0.41 (f D 1 2 1 8 8 .89, df = :	136 1 (P = (P = 0.6 55 95 21 70 241 3 (P = (7 ().85); ² = 8) 0 3 1 2 6 ().41); ² =	129 0% 57 90 19 70 236	7.6% 48.1% 16.0% 28.3%	1.24 (0.45, 3.42) 3.17 (0.13, 79.37) 0.62 (0.10, 3.82) 0.90 (0.05, 15.47) 4.39 (0.90, 21.45)			100
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: Z ecurrences MED VS OI Garg2011 Hussein2014 Righesso2007 Teli2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 2	9 .03, df = : 2 = 0.41 (f D 1 2 1 8 8 .89, df = :	136 1 (P = (P = 0.6 55 95 21 70 241 3 (P = (7 ().85); ² = 8) 0 3 1 2 6 ().41); ² =	129 0% 57 90 19 70 236	7.6% 48.1% 16.0% 28.3%	1.24 (0.45, 3.42) 3.17 (0.13, 79.37) 0.62 (0.10, 3.82) 0.90 (0.05, 15.47) 4.39 (0.90, 21.45)		0.1 1 10 MED/FE OD/MI	100
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: Z ecurrences MED VS OI Garg2011 Hussein2014 Righesso2007 Teli2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 2	9 .03, df = : 2 = 0.41 (f D 1 2 1 8 8 .89, df = :	136 1 (P = (P = 0.6 55 95 21 70 241 3 (P = (7 ().85); ² = 8) 0 3 1 2 6 ().41); ² =	129 0% 57 90 19 70 236 0%	7.6% 48.1% 16.0% 28.3%	1.24 (0.45, 3.42) 3.17 (0.13, 79.37) 0.62 (0.10, 3.82) 0.90 (0.05, 15.47) 4.39 (0.90, 21.45)			100
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: Z ecurrences MED VS OI Garg2011 Hussein2014 Righesso2007 Teli2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 2 Test for overall effect: Z	9 .03, df = 1 2 = 0.41 (f D 1 2 1 8 8 12 8 8 9, df = 1 2 = 1.34 (f	136 1 (P = (P = 0.6 55 95 21 70 241 3 (P = (P = 0.1	7 0.85); ² = 8) 0 3 1 2 6 ().41); ² = 8)	129 0% 57 90 19 70 236 0%	7.6% 48.1% 16.0% 28.3% 100.0%	1.24 [0.45, 3.42] 3.17 [0.13, 79.37] 0.62 [0.10, 3.82] 0.90 [0.05, 15.47] 4.39 [0.90, 21.45] 1.93 [0.74, 5.04]	⊢ 0.01	MED/FE OD/MI	100
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: Z ecurrences MED VS OF Garg2011 Hussein2014 Righesso2007 Teli2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 2 Test for overall effect: Z	9 .03, df = - 2 = 0.41 (f D 1 2 1 2 3 8 9, df = - 2 3 89, df = - 2 3 5 5 5 5 7 5 7 5 7 7 7 8 7 7 7 7 7 7 7 7	136 1 (P = (2 = 0.6 55 95 21 70 241 3 (P = (- = 0.1 Total	7 0.85); ² = 8) 0 3 1 2 6 0.41); ² = 8) MD Events	129 0% 57 90 19 70 236 0%	100.0% 7.6% 48.1% 16.0% 28.3% 100.0% Weight	1.24 [0.45, 3.42] 3.17 [0.13, 79.37] 0.62 [0.10, 3.82] 0.90 [0.05, 15.47] 4.39 [0.90, 21.45] 1.93 [0.74, 5.04] Odds Ratio M-H, Fixed, 95% C	⊢ 0.01	MED/FE OD/MI Odds Ratio	
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: Z ecurrences MED VS OI Garg2011 Hussein2014 Righesso2007 Teli2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 2 Test for overall effect: Z	9 .03, df = 1 2 = 0.41 (f D 1 2 1 8 8 12 8 8 9, df = 1 2 = 1.34 (f	136 1 (P = (P = 0.6 55 95 21 70 241 3 (P = (P = 0.1	7 0.85); ² = 8) 0 3 1 2 6 ().41); ² = 8)	129 0% 57 90 19 70 236 0%	100.0% 7.6% 48.1% 16.0% 28.3% 100.0% Weight 61.1%	1.24 [0.45, 3.42] 3.17 [0.13, 79.37] 0.62 [0.10, 3.82] 0.90 [0.05, 15.47] 4.39 [0.90, 21.45] 1.93 [0.74, 5.04] Odds Ratio	⊢ 0.01	MED/FE OD/MI Odds Ratio	100
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: Z ecurrences MED VS OI Garg2011 Hussein2014 Righesso2007 Teli2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 2 Test for overall effect: Z Study or Subgroup eatisfaction FE vs MD Ruetten2008 Ruetten2009	9 .03, df = - 2 = 0.41 (f D 1 2 1 8 8 9, df = 3 2 = 1.34 (f FE Events 88	136 1 (P = (P = 0.6 55 95 21 70 241 3 (P = (P = 0.1 Total 91	7 0.85); ² = 8) 0 3 1 2 6 0.41); ² = 8) MD Events 77	129 0% 57 90 19 70 236 0% 70 236 0%	100.0% 7.6% 48.1% 16.0% 28.3% 100.0% Weight	1.24 [0.45, 3.42] 3.17 [0.13, 79.37] 0.62 [0.10, 3.82] 0.90 [0.05, 15.47] 4.39 [0.90, 21.45] 1.93 [0.74, 5.04] Odds Ratio <u>M-H. Fixed, 95% C</u> 3.81 [1.01, 14.35] 3.58 [0.68, 18.85]	⊢ 0.01	MED/FE OD/MI Odds Ratio	100
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: Z ecurrences MED VS OF Garg2011 Hussein2014 Righesso2007 Teli2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 2 Test for overall effect: Z Study or Subgroup atisfaction FE vs MD Ruetten2008 Ruetten2009 Subtotal (95% CI) Total events	9 .03, df = - 2 = 0.41 (f D 1 2 1 8 8 , df = 3 2 2 = 1.34 (f FE Events 88 43 43 131	136 1 ($P = 0$ 55 95 21 70 241 3 ($P = 0$ Total 91 45 136	$\begin{array}{c} 7 \\ 0.85); ^2 = \\ 8) \\ 0 \\ 3 \\ 1 \\ 2 \\ 0.41); ^2 = \\ 8) \\ \hline \\ \underline{ Fvents} \\ 77 \\ 36 \\ 113 \end{array}$	129 0% 57 90 70 236 0% Total 87 42 129	100.0% 7.6% 48.1% 16.0% 28.3% 100.0% Weight 61.1% 38.9%	1.24 [0.45, 3.42] 3.17 [0.13, 79.37] 0.62 [0.10, 3.82] 0.90 [0.05, 15.47] 4.39 [0.90, 21.45] 1.93 [0.74, 5.04] Odds Ratio <u>M-H. Fixed, 95% Cl</u> 3.81 [1.01, 14.35]	⊢ 0.01	MED/FE OD/MI Odds Ratio	100
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: Z ecurrences MED VS OF Garg2011 Hussein2014 Righesso2007 Teli2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 2 Test for overall effect: Z Study or Subgroup attisfaction FE vs MD Ruetten2008 Ruetten2009 Subtotal (95% CI)	9 .03, df = - 2 = 0.41 (f D 1 2 1 8 8 12 2 = 1.34 (f Events 88 43 131 .00, df = -	136 1 ($P = 0$ 55 95 21 70 241 3 ($P = 0$ Total 91 45 136 1 ($P = 0$	$\begin{array}{c} 7\\ 0.85); ^{2} =\\ 8) \\ 0\\ 3\\ 1\\ 2\\ 0.41); ^{2} =\\ 8) \\ \hline \\ \underline{Events} \\ 77\\ 36\\ 113\\ 0.95); ^{2} =\\ \end{array}$	129 0% 57 90 70 236 0% Total 87 42 129	100.0% 7.6% 48.1% 16.0% 28.3% 100.0% Weight 61.1% 38.9%	1.24 [0.45, 3.42] 3.17 [0.13, 79.37] 0.62 [0.10, 3.82] 0.90 [0.05, 15.47] 4.39 [0.90, 21.45] 1.93 [0.74, 5.04] Odds Ratio <u>M-H. Fixed, 95% C</u> 3.81 [1.01, 14.35] 3.58 [0.68, 18.85]	⊢ 0.01	MED/FE OD/MI Odds Ratio	100
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: Z ecurrences MED VS OI Garg2011 Hussein2014 Righesso2007 Teli2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 2 Test for overall effect: Z Study or Subgroup tatisfaction FE vs MD Ruetten2008 Ruetten2009 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0	9 .03, df = - 2 = 0.41 (f D 1 2 1 8 8 12 2 = 1.34 (f Events 88 43 131 .00, df = -	136 1 ($P = 0$ 55 95 21 70 241 3 ($P = 0$ Total 91 45 136 1 ($P = 0$	$\begin{array}{c} 7\\ 0.85); ^{2} =\\ 8) \\ 0\\ 3\\ 1\\ 2\\ 0.41); ^{2} =\\ 8) \\ \hline \\ \underline{Events} \\ 77\\ 36\\ 113\\ 0.95); ^{2} =\\ \end{array}$	129 0% 57 90 70 236 0% Total 87 42 129	100.0% 7.6% 48.1% 16.0% 28.3% 100.0% Weight 61.1% 38.9%	1.24 [0.45, 3.42] 3.17 [0.13, 79.37] 0.62 [0.10, 3.82] 0.90 [0.05, 15.47] 4.39 [0.90, 21.45] 1.93 [0.74, 5.04] Odds Ratio <u>M-H. Fixed, 95% C</u> 3.81 [1.01, 14.35] 3.58 [0.68, 18.85]	⊢ 0.01	MED/FE OD/MI Odds Ratio	100

Figure. 3. (continued).

randomized controlled trials and only 1 was randomized controlled trial, which increased the risk of bias. Greater operative time will correspondingly increase the risk of intraoperative damage. Ondeck et al suggested that longer operative time was associated with higher risk of overall postoperative adverse events and multiple individual adverse outcomes.⁴² Therefore, we believe that MED may be able to achieve better control of intraoperative hemorrhage rather than intraoperative damage.

Shorter hospital stay means that patients could recover more quickly after surgery and return to normal work and life earlier,




Figure. 4. Pooling results of the PETD group and the PEID group. The results were shown as follows: VAS, ODI, Fluoroscopy Times, Operative Time, Postoperative Bedrest Time, Clinical Outcomes Evaluated by the Macnab Criteria, Complication Rate and Recurrence Rate.

which can indirectly reflect less surgical damage from the surgery. Zhang et al reported that transforaminal endoscopic discectomy was superior to open microdiscectomy in the length of hospital stay.⁴³ In this study, the length of hospital stay of PELD was shorter than FD. And there was no significant difference between MED and OD in the length of hospital stay. In several countries, however, the length of hospital stay is also associated with reimbursement issues.¹⁴ Thus, shorter hospital stay is supposed to reduce the cost of treatment. Due to lack of enough RCTs comparing the cost-effectiveness between different surgical techniques, further research is needed to determine which surgical technique is more cost-effective. Phana et al reported that the length of hospital stay of MED was shorter than OD.⁴⁴ We believe that this difference in results may be due to the conversion of units used for comparison. We compared the data according to the standardized mean difference instead of converting the data into uniform units and the original format of the data was preserved, which would increase the statistical reliability.

The complication rate of PELD was lower than FD (PELD: 4.3%; FD: 14.6%) and the complication rate of FE was lower than MD (FE: 13.4%; MD: 32.1%), both with statistical significance. And the complication rate of MED was higher than OD without statistical significance (MED: 19.5%; OD: 16.6%) in this study. To a certain extent, postoperative complications could reflect the intraoperative damage. Phana et al suggested that no statistical significance was found in complication rate




Figure 4. (continued).




Figure 5. Risk of bias summary.

between FE with OD and MED with OD.⁴⁴ We believe that this difference in results is mainly due to the different types of trials selected, and our studies are all based on pure randomized controlled trials for the comparison between MED and OD. Moreover, we included more high-quality RCTs comparing the complications of FE and OD. These findings on operative time, intraoperative blood loss, hospital stay and complication rate in our study suggested that PELD and FE are more advantageous in controlling intraoperative damage

In this study, we performed the comparison of VAS and ODI between PETD and FD at various time points during the follow-up period, as well as JOA and clinical outcomes evaluated by the Macnab criteria between PELD and FD, PELD and OD, lastly, MED and OD. Visual analog scale (VAS) is widely used to measure pain relief in spinal surgery. Oswestry Disability Index (ODI) and Japanese Orthopedic Association back pain evaluation questionnaire (JOA) are questionnaires evaluating dysfunction. And the Macnab criteria is mainly used to evaluate postoperative working and living conditions. The only statistically significant outcome in these comparisons was the VAS at 1 day after operation between PETD with FD. We believed that the reason for this result may be that PELD is more advantageous in controlling intraoperative damage and less intraoperative damage allows patients to recover more quickly, leading pain relief to come sooner. At present, none of these surgical techniques has been abandoned for

Table 3. Pooling Results of the ED Group and the NED Group. The
Results Were Shown as Follows: VAS Between PETD and FD, VAS
Between PELD and FD and JOA Between PELD and FD.

Trials	Participants	Mean difference (95%Cl)	P value ^a
3	250	-1.27 [-2.47 to -0.07]	.04
2	160	-1.56 [-4.29 to 1.18]	.26
2	140	-0.10 [-0.29 to 0.09]	.31
3	226	-0.14 [-0.34 to 0.06]	.17
3	266	-0.74 [-1.59 to 0.11]	.09
3	246	0.03 [-0.22 to 0.28]	.81
3	276	-1.01 [-2.66 to 0.63]	.23
_			
5	412	-0.42 [-0.98 to 0.13]	.13
4	332	0.11 [-0.38 to 0.60]	.65
	3 2 3 3 3 3 5	3 250 2 160 2 140 3 226 3 266 3 246 3 276 5 412	$\begin{array}{cccccccccccccccccccccccccccccccccccc$

Abbreviations: PETD, percutaneous endoscopic transforaminal discectomy; FD, fenestration discectomy; VAS, visual analog scale; ODI, Oswestry disability index; JOA, Japanese Orthopaedic Association back pain evaluation questionnaire.

 ${}^{\mathrm{a}}P$ value for heterogeneity between interventions calculated by using mixed-effects models.

symptomatic LDH. Many studies suggested that open surgery, minimally invasive surgery and spinal endoscopic surgery are considered as sufficient and safe techniques with good clinical outcomes.^{14,41,44-46} Open discectomy is still considered as the gold standard treatment for symptomatic LDH.^{47,48} The findings of this study suggested that there was no difference in achieving pain relief, functional recovery, and quality of life improvement among these surgical techniques. All of these surgical techniques can be considered sufficient to achieve good clinical outcomes.

Some studies suggested that the reoperation rate of ED was higher than that of NED due to the steep learning curve and the limited operative field of ED.^{12,49-51} The study of Qin et al⁵² and Ruan et al⁴¹ reported that there was no statistical significance between PELD and OD in the rate of reoperation. But it is worth mentioning that misclassifications of trials appeared in this comparison in both studies. The trial of Ruetten et al published in 2008²⁸ included in the study of Qin et al⁵² and the trial of Ruetten et al published in 200953 included in the study of Ruan et al⁴¹ were misclassified. The interventions of these 2 trials were full-endoscopic discectomy rather than percutaneous endoscopic lumbar discectomy. After accurate classification in this study, there was no significant difference in the rate of reoperation between MED and OD (MED: 6.3%; OD: 6.0%) or FE and MD (FE: 6.1%; MD: 7.0%) and no significant significance in the rate of recurrence was found between MED and OD (MED: 5.0%; OD: 2.5%) or FE and MD (FE: 6.6%; MD: 5.4%). The findings of this study suggested that ED (FE

and MED) and NED could achieve similar results in the rate of reoperation and recurrence. Due to lack of high-quality RCTs, comparison of the rate of reoperation and recurrence between PELD and OD needs further research.

PELD can be classified as percutaneous endoscopic transforaminal discectomy (PETD) or percutaneous endoscopic interlaminar discectomy (PEID) according to the surgical approach. Some studies suggested that the indications for these 2 approaches were different. Since PEID is not affected by the height of the iliac crest, patients with high iliac crest are suitable for the interlaminar approach but the nerve roots are more easily stimulated during surgery, resulting in poor intraoperative tolerance.^{35,36} PETD is suitable for patients with interlaminar stenosis or tension phenotype.³⁹ In this study with 5 RCTs introduced, we performed the comparisons of VAS, ODI, postoperative bed time, fluoroscopy times, operative time, clinical outcomes evaluated by the Macnab criteria, complication rate and recurrence rate between PETD with PEID. The fluoroscopy time of PEID was less than PETD and the operative time of PEID was statistically shorter than PETD with statistical significance but no significance was found in the remaining comparisons. The reasons for these results may be that the anatomical structure and technique during PEID are very similar to traditional open discectomy, which let the surgeons adapt to this approach very quickly and make the introduction of endoscope relatively simple. Based on these findings, we believe that both PETD and PEID are able to achieve similar results but the learning curve of PETD was steeper.

The objective of this study was to systematically compare the effectiveness and safety of endoscopic discectomy with non-endoscopic discectomy for the treatment of symptomatic LDH. Many published studies have performed the comparison of the same topic without pure RCTs included.^{41,43-46} The advantage of this study is greater number of high-quality RCTs are available that compared ED and NED allowing more accurate classification of interventions. And we performed a series of comparisons and subgroup analyzes based on each surgical procedures of MED, PELD (PETD and PEID) and FE for conducting more scientific and comprehensive results. We believed that these findings of this study could provide surgeons and patients with not only the choice of open discectomy or endoscopic discectomy, but also a more thorough and accurate selection of each surgical procedures on discectomy. By considering all included trials without language restrictions, this study could avoid outcomes distorted by language bias. But there were still several limitations in this study. First, the number of trials involved in some comparisons are relatively small. The cost-effectiveness of discectomy for symptomatic LDH has rarely been reported in studies, despite its need.⁵⁴ Only 1 trial included in this study reported that MED was more expensive than OD with statistical significance.³² And due to the lack of high-quality RCTs, comparisons could not be performed for all surgical approaches for some outcomes. Second, differences existed in the inclusion criteria and patient characteristics between some trials and the follow-up period in the trial of Hussein et al¹⁹ significantly longer than other trials, resulting in statistically significant heterogeneity in some results. Third, clear allocation concealment and complete outcome data were not presented in some trials. And some trials failed to fully describe the baseline characteristics of patients.

Conclusion

PELD and FE are more advantageous in controlling intraoperative damage. Both ED and NED can be considered sufficient to achieve good clinical outcomes. In subgroup analyzes, ED (FE and MED) could achieve similar results in the rate of reoperation and recurrence compared with NED. Both PETD and PEID are able to achieve similar results but the learning curve of PETD was steeper. More independent high-quality RCTs using sufficiently large sample sizes and performing costeffectiveness analyzes are needed.

Authors' Note

Contributors WSL did study concept and design, data acquisition and interpretation, and drafted the manuscript; QY did data acquisition, data interpretation and language editing; LC did study concept and design, study supervision, and critical review of the manuscript. All authors reviewed the study findings and read and approved the final version before submission.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by National Natural Science Foundation of China (NO: 81871803). The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

ORCID iD

Lin Cong, PhD (https://orcid.org/0000-0001-9951-5239

References

- Gadjradj PS, Arts MP, van Tulder MW, Rietdijk WJR, Peul WC, Harhangi BS. Management of symptomatic lumbar disk herniation: an international perspective. *Spine (Phila Pa 1976)*. 2017; 42(23):1826-1834.
- Kerr D, Zhao W, Lurie JD. What are long-term predictors of outcomes for lumbar disc herniation? A randomized and observational study. *Clin Orthop Relat Res.* 2015;473(6):1920-1930.
- Frymoyer JW. Back pain and sciatica. N Engl J Med. 1988; 318(5):291-300.
- Mixter WJ, Barr JS. Rupture of the intervertebral disc with involvement of the spinal canal. N Engl J Med. 1934;211(5):210-215.
- 5. Iwa H, Caspar W. A microsurgery operation for lumbar disc herniation (author's transl). *No Shinkei Geka*. 1978;6(7):657-662.
- Yasargil MG, Vise WM, Bader DC. Technical adjuncts in neurosurgery. *Surg Neurol.* 1977;8(5):331-336.
- Foley KT, Smith MM, Rampersaud YR. Microendoscopic approach to far-lateral lumbar disc herniation. *Neurosurg Focus*. 1999;7(5):e5.

- Kambin P. Arthroscopic microdiskectomy. *Mt Sinai J Med.* 1991; 58(2):159-164.
- Leu H, Schreiber A. Percutaneous nucleotomy with disk endoscopy—a minimally invasive therapy in non-sequestrated intervertebral disk hernia. *Schweiz Rundsch Med Prax*. 1991;80(14): 364-368.
- Mayer HM, Brock M, Berlien HP, Weber B. Percutaneous endoscopic laser discectomy (PELD). A new surgical technique for non-sequestrated lumbar discs. *Acta Neurochir Suppl (Wien)*. 1992;54:53-58.
- Hoogland T, Schubert M, Miklitz B, Ramirez A. Transforaminal posterolateral endoscopic discectomy with or without the combination of a low-dose chymopapain: a prospective randomized study in 280 consecutive cases. *Spine (Phila Pa 1976)*. 2006; 31(24):E890-E897.
- Yeung AT, Tsou PM. Posterolateral endoscopic excision for lumbar disc herniation: surgical technique, outcome, and complications in 307 consecutive cases. *Spine (Phila Pa 1976)*. 2002; 27(7):722-731.
- Ruetten S, Komp M, Godolias G. An extreme lateral access for the surgery of lumbar disc herniations inside the spinal canal using the full-endoscopic uniportal transforaminal approachtechnique and prospective results of 463 patients. *Spine (Phila Pa 1976)*. 2005;30(22):2570-2578.
- Cong L, Zhu Y, Tu G. A meta-analysis of endoscopic discectomy versus open discectomy for symptomatic lumbar disk herniation. *Eur Spine J.* 2016;25(1):134-143.
- Garg B, Nagraja UB, Jayaswal A. Microendoscopic versus open discectomy for lumbar disc herniation: a prospective randomised study. *J Orthop Surg (Hong Kong)*. 2011;19(1):30-34.
- Gibson JNA, Subramanian AS, Scott CEH. A randomised controlled trial of transforaminal endoscopic discectomy vs microdiscectomy. *Eur Spine J.* 2017;26(3):847-856.
- Hermantin FU, Peters T, Quartararo L, Kambin P. A prospective, randomized study comparing the results of open discectomy with those of video-assisted arthroscopic microdiscectomy. *J Bone Joint Surg Am.* 1999;81(7):958-965.
- Huang TJ, Hsu RW, Li YY, Cheng CC. Less systemic cytokine response in patients following microendoscopic versus open lumbar discectomy. *J Orthop Res.* 2005;23(2):406-411.
- Hussein M, Abdeldayem A, Mattar MM. Surgical technique and effectiveness of microendoscopic discectomy for large uncontained lumbar disc herniations: a prospective, randomized, controlled study with 8 years of follow-up. *Eur Spine J.* 2014;23(9): 1992-1999.
- Jin D, Xu N, Zhao G. Comparative study of percutaneous transforaminal endoscopic discectomy versus fenestration discectomy in patients with lumbar disc herniation. *Chin J Min Inv Surg.* 2017;17(6):491-494.
- Komp M, Hahn P, Oezdemir S, et al. Bilateral spinal decompression of lumbar central stenosis with the full-endoscopic interlaminar versus microsurgical laminotomy technique: a prospective, randomized, controlled study. *Pain Physician*. 2015;18(1):61-70.
- 22. Lee SH, Chung SE, Ahn Y, Kim TH, Park JY, Shin SW. Comparative radiologic evaluation of percutaneous endoscopic lumbar

discectomy and open microdiscectomy: a matched cohort analysis. *Mt Sinai J Med*. 2006;73(5):795-801.

- Liu J, Zhen W, Gao G, et al. A prospective and controlled study of percutaneous transforaminal endoscopic discectomy vercus fenestration discectomy for lumbar disc herniation. *Chinses J Bone Joint*. 2014;3(4):245-250.
- Mayer HM, Brock M. Percutaneous endoscopic discectomy: surgical technique and preliminary results compared to microsurgical discectomy. *J Neurosurg*. 1993;78(2):216-225.
- Pan L, Zhang P, Yin Q. Comparison of tissue damages caused by endoscopic lumbar discectomy and traditional lumbar discectomy: a randomised controlled trial. *Int J Surg.* 2014;12(5): 534-537.
- Pan Z, Ha Y, Yi S, Cao K. Efficacy of transforaminal endoscopic spine system (TESSYS) technique in treating lumbar disc herniation. *Med Sci Monit*. 2016;22:530-539.
- Righesso O, Falavigna A, Avanzi O. Comparison of open discectomy with microendoscopic discectomy in lumbar disc herniations: results of a randomized controlled trial. *Neurosurgery*. 2007;61(3):545-549.
- Ruetten S, Komp M, Merk H, Godolias G. Full-endoscopic interlaminar and transforaminal lumbar discectomy versus conventional microsurgical technique: a prospective, randomized, controlled study. *Spine (Phila Pa 1976)*. 2008;33(9):931-939.
- Ruetten S, Komp M, Merk H, Godolias G. Recurrent lumbar disc herniation after conventional discectomy: a prospective, randomized study comparing full-endoscopic interlaminar and transforaminal versus microsurgical revision. *J Spinal Disord Tech.* 2009; 22(2):122-129.
- Tacconi L, Signorelli F, Giordan E. Surgery is full endoscopic lumbar discectomy less invasive than conventional? A randomized MRI study. *World Neurosurg*. 2020;138:e867-e875.
- Tang G, Huang Q, Zhang W. Preliminary outcomes of percutaneous transformational endoscopic lumbar discectomy for elder patients with lumbar disc herniation. *China J Endoscopy*. 2012; 18(12):1300-1303.
- Teli M, Lovi A, Brayda-Bruno M, et al. Higher risk of Dural tears and recurrent herniation with lumbar micro-endoscopic discectomy. *Eur Spine J.* 2010;19(3):443-450.
- Wang S, Pan L, Huang B. Comparative study on percutaneous transforaminal endoscopic discectomy and small incision method for lumbar disc herniation. *J Pract Orthop.* 2015;21(4):293-296.
- Wu J, Ge B, Wu D. A comparison between intervertebral fenestration and percutaneous transforaminal endoscopic discectomy for treatment of lumbar disc herniation. *Orthop J China*. 2016; 24(21):1972-1976.
- Chen Z. Comparison of percutaneous endoscopic through different surgical treatment for lumber disc herniation. J Medical Forum. 2015;36(6):39-42.
- Huang H, Yang B, Song J. A comparison of surgical treatment effect of L5 / S1 herniated disc under different percutaneous endoscopy. *Lab Med Clin.* 2017;14(11):1651-1653.
- Mo X, Shen J, Jiang W, et al. Percutaneous endoscopic lumbar diskectomy for axillar herniation at L5-S1 via the transforaminal approach versus the interlaminar approach: a prospective clinical trial. *World Neurosurg*. 2019;125:e508-e514.

- Nie H, Zeng J, Song Y, et al. Percutaneous endoscopic lumbar discectomy for L5-S1 disc herniation via an interlaminar approach versus a transforaminal approach: a prospective randomized controlled study with 2-year follow up. *Spine (Phila Pa* 1976). 2016;41(suppl 19):B30-B37.
- Xu Z, Shi L, Chu L, Chen L, Ke Z, Deng Z. Comparison of percutaneous endoscopic via interlaminar and transforaminal approach for lumbar disc herniation. *J Spinal Surg.* 2013;11(2): 97-100.
- Nakagawa H, Kamimura M, Uchiyama S, Takahara K, Itsubo T, Miyasaka T. Microendoscopic discectomy (MED) for lumbar disc prolapse. *J Clin Neurosci.* 2003;10(2):231-235.
- Ruan W, Feng F, Liu Z, Xie J, Cai L, Ping A. Comparison of percutaneous endoscopic lumbar discectomy versus open lumbar microdiscectomy for lumbar disc herniation: a meta-analysis. *Int J Surg.* 2016;31:86-92.
- Ondeck NT, Bohl DD, McLynn RP, et al. Longer operative time is associated with increased adverse events after anterior cervical diskectomy and fusion: 15-minute intervals matter. *Orthopedics*. 2018;41(4):e483-e488.
- Zhang B, Liu S, Liu J, et al. Transforaminal endoscopic discectomy versus conventional microdiscectomy for lumbar disc herniation: a systematic review and meta-analysis. *J Orthop Surg Res.* 2018;13(1):169.
- Phan K, Xu J, Schultz K, et al. Full-endoscopic versus microendoscopic and open discectomy: a systematic review and meta-analysis of outcomes and complications. *Clin Neurol Neurosurg.* 2017;154:1-12.
- 45. Alvi MA, Kerezoudis P, Wahood W, Goyal A, Bydon M. Operative approaches for lumbar disc herniation: a systematic review and multiple treatment meta-analysis of conventional and minimally invasive surgeries. *World Neurosurg*. 2018;114:391-407.e392.
- 46. Kim M, Lee S, Kim HS, Park S, Shim SY, Lim DJ. A comparison of percutaneous endoscopic lumbar discectomy and open lumbar microdiscectomy for lumbar disc herniation in the Korean: a meta-analysis. *Biomed Res Int.* 2018;2018:9073460.
- Casal-Moro R, Castro-Menéndez M, Hernández-Blanco M, Bravo-Ricoy JA, Jorge-Barreiro FJ. Long-term outcome after microendoscopic diskectomy for lumbar disk herniation: a prospective clinical study with a 5-year follow-up. *Neurosurgery*. 2011;68(6):1568-1575.
- Perez-Cruet MJ, Foley KT, Isaacs RE, et al. Microendoscopic lumbar discectomy: technical note. *Neurosurgery*. 2002;51(5 suppl):S129-136.
- Goald HJ. Microlumbar discectomy: follow-up of 477 patients. J Microsurg. 1980;2(2):95-100.
- Kim MJ, Lee SH, Jung ES, et al. Targeted percutaneous transforaminal endoscopic diskectomy in 295 patients: comparison with results of microscopic diskectomy. *Surg Neurol.* 2007;68(6): 623-631.
- Schaffer JL, Kambin P.Percutaneous posterolateral lumbar discectomy and decompression with a 6.9-millimeter cannula. Analysis of operative failures and complications. *J Bone Joint Surg Am.* 1991;73(6):822-831.
- 52. Qin R, Liu B, Hao J, et al. Percutaneous endoscopic lumbar discectomy versus posterior open lumbar microdiscectomy for the

treatment of symptomatic lumbar disc herniation: a systemic review and meta-analysis. *World Neurosurg*. 2018;120:352-362.

53. Ruetten S, Komp M, Merk H, Godolias G. Surgical treatment for lumbar lateral recess stenosis with the full-endoscopic interlaminar approach versus conventional microsurgical technique: a prospective, randomized, controlled study. *J Neurosurg Spine*. 2009;10(5):476-485.

 Gibson JN, Waddell G. Surgical interventions for lumbar disc prolapse: updated Cochrane review. *Spine (Phila Pa 1976)*. 2007;32(16):1735-1747.